JERUSALEM--(BUSINESS WIRE)--April 10, 2006--BioLineRx Ltd., Israel’s leading drug development company, announced today the initiation of a randomized, placebo-controlled Phase 1 clinical trial to evaluate the safety and determine the pharmacokinetic profile of BL-1020, a first in class, proprietary small molecule for the treatment of schizophrenia. The Phase 1 clinical trial is designed as a double blind, single dose-escalation study and will be conducted at Sourasky Medical Center, Tel Aviv, Israel.
